Press Releases
Kaplan Fox & Kilsheimer LLP Encourages Beta Bionics, Inc. (BBNX) Investors With Losses to Seek Appointment as Lead Plaintiff Before November 3, 2026
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: BBNX) on behalf of investors that purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Beta Bionics and have suffered losses, you may CLICK HERE to contact us...
Kaplan Fox Advises Endava plc (DAVA) Investors to Act Before the Lead Plaintiff Deadline on November 30, 2026
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Endava plc ("Endava" or the "Company") (NYSE: DAVA) on behalf of investors that purchased or otherwise acquired Endava securities between September 4, 2025 and September 21, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Endava and have suffered losses, you may CLICK HERE to contact us...
Kaplan Fox Urges Investors of AppLovin Corporation (APP) to Seek a Leadership Role Before November 16, 2026
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against AppLovin Corporation ("AppLovin" or the "Company") (NASDAQ: APP) on behalf of investors that purchased or otherwise acquired AppLovin securities between February 12, 2026 and August 5, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in AppLovin and have suffered losses, you may CLICK HERE to contact us...
Kaplan Fox Advises Fluence Energy, Inc. (FLNC) Investors to Act Before the Lead Plaintiff Deadline on November 27, 2026
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Fluence Energy, Inc. ("Fluence Energy" or the "Company") (NASDAQ: FLNC) on behalf of investors that purchased or otherwise acquired Fluence Energy securities between November 24, 2025 and September 16, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Fluence Energy and have suffered losses, you may CLICK HERE to contact us...
Kaplan Fox Reminds AST SpaceMobile, Inc. (ASTS) Investors to Seek a Leadership Role Before Deadline on November 13, 2026
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against AST SpaceMobile, Inc. ("AST" or the "Company") (NASDAQ: ASTS) on behalf of investors that purchased or otherwise acquired AST securities between March 4, 2025 and July 15, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in AST and have suffered losses, you may CLICK HERE to contact us...
Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform
Montreal, Quebec--(Newsfile Corp. - October 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum drug-delivery platform, is pleased to announce two significant achievements at World ADC San Diego 2026, held October 12-15: winning the conference's Best Poster Award for its Accum -ADC research and leading a main-stage discussion alongside internationally recognized experts in antibody-drug conjugates ("ADCs"). These achievements highlight the growing recognition of Defence's Accum technology within the global ADC community...
IMU and UK Biobank to generate the world's most detailed, large-scale picture of the human immune system for advancing research into health and disease
LONDON--(BUSINESS WIRE)--IMU Biosciences (‘IMU or the ‘Company'), a biotechnology company using its High Definition Immunology™ platform to better understand the immune system and drive a shift in how we understand, diagnose, and treat disease, has today announced a new collaboration with UK Biobank to generate large-scale multi-omic immune profiling data from 80,000 blood samples collected from UK Biobank participants. The project will use IMU's HD Immunology™ platform in conjunction with Wate...
Kaplan Fox Advises Hyliion Holdings Corp. (HYLN) Investors to Act Before the Lead Plaintiff Deadline on October 27, 2026
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hyliion Holdings Corp. ("Hyliion Holdings" or the "Company") (NYSE American: HYLN) on behalf of investors that purchased or otherwise acquired Hyliion Holdings securities between May 12, 2026 and June 23, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Hyliion Holdings and have suffered losses, you may CLICK HERE to contact us...
Kaplan Fox Advises Investors of AEVEX Corp. (AVEX) to Contact the Firm Before the Deadline on October 20, 2026
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against AEVEX Corp. ("AEVEX Corp" or the "Company") (NYSE: AVEX) on behalf of investors that purchased or otherwise acquired AEVEX Corp Class A Common Stock pursuant and/or traceable to the Company's initial public offering on or about April 17, 2026 ("IPO"), or between April 17, 2026 and June 4, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in AEVEX Corp and have suffered losses, you may CLICK HERE to contact us...
BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate
VANCOUVER, BC / ACCESS Newswire / October 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce two major development milestones for BNT23001, its proprietary sublingual Cladribine oral dissolvable film ("ODF") drug candidate for the treatment of relapsing forms of multiple sclerosis ("MS"). The Company has completed Good Manufacturing Practice ("GMP") manufacturing of approximately 1,500 investigational Cladribine films and submitted its Clinical Trial Application ("CTA") through the European Union's Clinical Trials Information System ("CTIS") on October 16, 2026...
Christmas flights 2026: KAYAK reveals fares down up to 39% from the UK
LONDON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Flight prices to selected destinations from the UK have fallen for Christmas and New Year travel, with average return flights down up to 39% compared to last year, according to travel search engine KAYAK's Christmas Travel Check-in 2026 . US destinations lead KAYAK's flight price drop rankings with average returns from the UK to Atlanta down 39% year-on-year, followed by Washington DC (-27%) and Los Angeles (-20%)...
Lazard Welcomes David Krap as Managing Director and Co-Head of European Consumer, Retail & Leisure
LONDON, Oct. 19, 2026 /PRNewswire/ -- Lazard, Inc. (NYSE: LAZ) today announced the appointment of David Krap as Managing Director and Co-Head of European Consumer, Retail & Leisure. David brings over two decades of consumer-focused M&A advisory experience, with a particular focus on food and beverage, home and personal care, and select consumer health categories...
Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma...
Elbit Systems Awarded $235 Million Contract to Supply EXTRA-MR Rockets and PULS Launchers to a European Country
HAIFA, Israel, Oct. 19, 2026 /PRNewswire/ -- Elbit Systems Ltd. (NASDAQ: ESLT) (TASE: ESLT) ("Elbit Systems" or the "Company") announced today that it was awarded a contract valued at approximately $235 million to supply EXTRA-MR (Medium Range) rockets and Precise & Universal Launching System (PULS™) rocket artillery systems to a European customer, under a government-to-government (G-to-G) agreement between the Israel Ministry of Defense and the customer country's Ministry of Defense...
Capitan Expands High-Grade Silver Mineralization to 600 Metres Down-Dip and Announces New CRD Discovery at Cruz De Plata
Vancouver, British Columbia--(Newsfile Corp. - October 19, 2026) - Capitan Silver Corp. (TSXV: CAPT) (OTCQX: CAPTF) ("Capitan" or "the Company") is pleased to report additional results from its 60,000-metre drill program at its Cruz de Plata silver-gold project, located in Durango, Mexico. The Company is reporting assay results from twenty-two (22) drill holes...
PetroTal Announces Board Change and Appointment of Emily Morris as Head of Investor Relations
Calgary, Alberta and Houston, Texas--(Newsfile Corp. - October 19, 2026) - PetroTal Corp. (TSX: TAL) (AIM: PTAL) (OTCQX: PTALF) ("PetroTal" or the "Company") is pleased to announce the appointment of Emily Morris as Head of Investor Relations. Based in London, Ms.
Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
Markviss innritun sjúklinga með auknar líkur á meðferðarsvörun: 2/3 af þeim 176 sjúklingum sem innritaðir voru bera þann TNFR1-erfðabreytileika sem tengdur hefur verið aukinni klínískri svörun í fasa 2 rannsóknum.
PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026
BOSTON--(BUSINESS WIRE)--PureTech Announces Presentation of Phase 1b Results for LYT-200 in R/R High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia at ESMO 2026.
Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease
High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials
Caledonia Mining Corporation Plc: Notification of Relevant Change To Significant Shareholder
(NYSE AMERICAN:CMCL)(AIM:CMCL)(VFEX:CMCL) SAINT HELIER, JE / ACCESS Newswire / October 19, 2026 / Caledonia Mining Corporation Plc ("Caledonia" or "the Company") announces that it received notification on October 16, 2026 from BlackRock, Inc. that on October 15, 2026 it had crossed a threshold for notification of a relevant change (as defined by the AIM Rules for Companies). A copy of the notification is below...
Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix
The joint venture between IBA and Framatome will leverage Telix's capabilities to accelerate the production and availability of Astatine-211 in the US market.
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
MELBOURNE, Australia and LOUVAIN-LA-NEUVE, Belgium and PARIS and INDIANAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Ekalia, a joint venture between IBA (Ion Beam Applications S.A., EURONEXT) and Framatome, today announced a collaboration to advance scalable United States (U.S.) production of astatine-211 (211At), an alpha-emitting radioisotope being investigated for targeted alpha therapy...
Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830
Press release – No. 21 / 2026 Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 ZP9830 is a novel Kv1.3 ion channel blocker with pipeline-in-a-product opportunity across a broad range of cell-mediated autoimmune diseases Multiple doses of ZP9830 were well tolerated with no serious or severe adverse events or dose-limiting safety findings Development program is progressing rapidly with a Phase 1b trial in people with plaque psoriasis recently initiated, and a Phase 2 trial in an additional autoimmune disease planned for initiation in H1 2027 Copenhagen, Denmark, October 19, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no...
Red Cat Announces Proposed Voluntary Public Purchase Offer for Steyr Motors
Proposed transaction represents a strategic investment in Austria and would support Steyr Motors' long-term growth and Red Cat's Blue Ops uncrewed surface vessel strategy Proposed transaction represents a strategic investment in Austria and would support Steyr Motors' long-term growth and Red Cat's Blue Ops uncrewed surface vessel strategy
Tsodilo Resources Ltd Advances in Multiple Strategic Collaborations - Botswana Institute for Technology Research & Innovation, University of Cape Town and Battelle Memorial Institute on Efforts to Advance Critical Minerals and Rare Earth Element Exploration
Toronto, Ontario--(Newsfile Corp. - October 19, 2026) - Tsodilo Resources Ltd. (TSXV: TSD) (OTCQB: TSDRF) (FSE: TZO) ("Tsodilo" or the "Company") is pleased to provide an update on its strategic collaborative research alliances supporting its critical minerals ("CM") and rare earth element exploration ("REE") at the 100% owned Gcwihaba Metals Project in Northwest Botswana...
Infleqtion Convenes Business Leaders in London to Chart Quantum Commercial Value
OXFORD, England--(BUSINESS WIRE)--Infleqtion (NYSE: INFQ), a global leader in quantum computing and quantum sensing powered by neutral atom technology, will host the first Quantum Application Forum, an exclusive one-day event convening senior business and technology leaders on 3 November 2026 at IET Savoy Place in London. Executives responsible for technology, innovation and investment decisions will explore how quantum technology can address critical challenges, unlock commercial value and dri...
FF EAI Robotics Ecosystem Inc. (FFR) Highlights Faraday Future Founder and Global CEO YT Jia's Weekly Investor Update: Three New Product Offerings Launched; More Details on FFR's Acquisition of FFAI's Robotics Business and Independent Public Listing
On October 26, FFR will hold its listing ceremony and first Investor Day at the Nasdaq Tower in New York, where management will share more about FFR's strategy and business plans, with more details to follow soon. Two new EAI Devices launched including FF Nova—America's first entry-level EAI humanoid robot under $2,500, and the second is Nova Mini, a humanoid robot for foundational Physical AI education, priced at $299, with the accompanying curriculum at $499...
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight as the Agentic Foundation for Its Up to $1 Billion Tokenized Solar and AI Computing Program with Meridian and Up to $130 Million IP-Backed Transaction with BeyondAI
LAKE MARY, Fla.--(BUSINESS WIRE)--OpenWorld, Inc. (“OpenWorld” or the “Company”) (NASDAQ: OPNW), an innovation company advancing global real-world asset (“RWA”) tokenization, today announced the signing of a definitive merger agreement to acquire Blocksight and outlined how its acquisition of Blocksight Holdings Co. (“Blocksight”), announced on October 1, 2026, is intended to serve as the operating foundation for the Company's tokenized financing programs in infrastructure and energy. Blocksigh...
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight
OpenWorld (NASDAQ: OPNW) Signs Definitive Merger Agreement to Acquire Blocksight as the Agentic Foundation for Its Up to $1 Billion Tokenized Solar and AI Computing Program with Meridian and Up to $130 Million IP-Backed Transaction with BeyondAI. Blocksight's AI agents are expected to handle deal structuring, asset verification, investor onboarding and daily reporting across more than $1.1 billion in recently announced tokenized financing programs on the OpenWorld Enterprise platform
Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: FFR to Hold Listing Ceremony and First Investor Day at the Nasdaq Tower on Oct. 26; Three New Robotics Product Offerings Launched
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global Embodied AI (EAI) ecosystem company, today shared a weekly business update from YT Jia, Founder and Global CEO of FF. “Welcome to Weekly Report 77. This week, let's start with some big news from FFR. On October 26, we will hold FFR's listing ceremony and first Investor Day at the Nasdaq Tower in New York. Our management team will share more a...
BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 2026
BioInvent International (STO:BINV) - Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in Platinum-Resistant Recurrent Ovarian Cancer (PRROC)" to be presented at ESMO on October 24 The abstract was published today on the ESMO website. It repeats data presented at ASCO 2026 (25 evaluable patients, cutoff May 6, 2026) Objective response rate was 24% (6 of 25 evaluable patients): 1 complete response and 5 partial responses with durable disease control Preliminary median progression-free survival (PFS) according to RECIST was 4.2 months...
AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio
New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicine AbbVie's largest ESMO presence to date highlights longer-term survival data, combination and biomarker findings from multiple assets across various stages of development Presentations across investigational and approved medicines to feature Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Emrelis™ (telisotuzumab vedotin-tllv) and Elahere (mirvetuximab soravtansine-gynx) NORTH CHICAGO, Ill., Oct. 18, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23-27 in Madrid, Spain...
ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23–26 in Madrid, Spain.New evidence highlights the power of Natera's latest ultrasensitive molecular residual disease (MRD) technology, Signatera Genome with Phased and Structural Variants, which has demonstrat...
Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
First Phase 1 data for sofetabart mipitecan, Lilly's investigational FR α -targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentation Updated first-line data for olomorasib, an investigational therapy targeting KRAS G12C-mutant NSCLC, to be featured in a rapid oral presentation Updated Phase 3 data for selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant MTC to be shared in a proffered paper INDIANAPOLIS, Oct. 18, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23–27 in Madrid, Spain. Highlights include new Phase 1 data in platinum-sensitive ovarian cancer (PSOC) for sofetabart mipitecan (Sofe-M), Lilly's investigational FRα-targeting antibody-drug conjugate (ADC), in combination with bevacizumab, along with updated findings for olomorasib, Retevmo (selpercatinib), and Verzenio (abemaciclib) in lung, thyroid, and breast cancers, respectively...
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Presentations to cover updates across Eikon's clinical pipeline including: Updated data from TeLuRide-005, an ongoing open-label Phase 2 trial of EIK1001, a TLR7/8 dual-agonist, plus pembrolizumab and histology-appropriate chemotherapy in stage 4 non-small cell lung cancer (NSCLC) Updated cohort data from an ongoing Phase 1/2 study of EIK1003, a highly selective non-brain penetrant PARP1 inhibitor, as monotherapy and in combination with chemotherapy in advanced solid tumors Initial data from a Phase 1/2 study of EIK1003 in combination with the novel hormonal agent abiraterone in metastatic prostate cancer Initial results from an ongoing Phase 1/2 study of EIK1004, a highly selective CNS-penetrant PARP1 inhibitor in advanced solid malignancies Preliminary safety, tolerability and pharmacokinetic data for EIK1005, a Werner (WRN) helicase inhibitor MILLBRAE, Calif., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the publication of full-text abstracts from its four clinical candidates to be presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain beginning on October 23, 2026...
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
SAN DIEGO, Oct. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that overall survival (OS) data from an interim analysis of the DENALI Part 1b study (GOG-3066) have been published in the abstract for the upcoming rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026...
Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ESMO2026--Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026.
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Monday, October 19, 2026, at 8:00 am ET to review results from Part A of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial (Study ‘304') evaluating VDPHL01, a proprietary, extended-re...
Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)
WATERTOWN, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it will host a corporate webcast to discuss topline results from the APOLLO Phase 3 trial of bitopertin in EPP. The webcast will be held on Monday, October 19, 2026 at 8:00 a.m. ET...
Cambria Gold Mines Intersects 98.56 g/t Gold over 8.2 Metres at the Silver Coin Deposit, Premier Gold Project
VANCOUVER, British Columbia, Oct. 18, 2026 (GLOBE NEWSWIRE) -- Cambria Gold Mines Inc. (TSXV: CAMB; OTCQX: CAMVF) (“Cambria” or the “Company”) is pleased to announce new assay results from the ongoing infill drilling program at the Premier Mining Complex (the “Premier Gold Project” or “PGP”), located near Stewart in northwestern British Columbia. Results from four diamond drillholes totalling 657 metres are reported herein. Highlight intervals include:
Evercore Appoints Nigel Dawn and Naveen Nataraj as Co-Presidents
NEW YORK--(BUSINESS WIRE)--Evercore (NYSE: EVR) today announced that its Board of Directors has appointed Nigel Dawn and Naveen Nataraj as Co-Presidents of the firm, effective January 1, 2027. Mr. Dawn and Mr. Nataraj will report to Chairman and Chief Executive Officer John S. Weinberg, who will continue to lead Evercore, its Management Committee and the firm's strategic direction. Evercore's Board and Mr. Weinberg have agreed that he will serve as Chairman and CEO for at least the next three y...
“Where Are the Numbers?” Doug Bergeron Calls on Ethan Allen to Release First Quarter Results Before November 4 Board Vote
PARK CITY, Utah--(BUSINESS WIRE)--Doug Bergeron, a significant shareholder of Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD) with beneficial ownership, collectively with his affiliates and associates, of approximately 5.2% of Ethan Allen's outstanding common stock, today called on Ethan Allen to announce when it will release its fiscal first quarter 2027 financial results and to publish those results sufficiently ahead of its 2026 Annual Meeting of Stockholders (the “An...
Changes to the Board of Directors of H. Lundbeck A/S
Dorothea Wenzel, Chair of the Board, has informed the Board that she will step down in connection with the Annual General Meeting in 2027. Following the AGM, Lundbeck's Board intends to appoint Lars Fruergaard Jørgensen as the new Chair.
Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026
WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre's IBD antibodies—SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)—which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data demonstrating additive efficacy of these complementary mechanisms...
Fujifilm Introduces FUJIFILM HX1024 Printbar System
LEBANON, N.H.--(BUSINESS WIRE)--FUJIFILM Integrated Inkjet Solutions today announced the introduction of the FUJIFILM HX1024 Printbar System, designed to support customized printing using the company's advanced inkjet printing technologies. Developed as part of Fujifilm's comprehensive approach to print solutions, the system delivers high-quality, high-speed, full-color digital inkjet printing for a variety of construction products, including house wrap, sandpaper, drywall, laminates, and more...
FOXF Investors with $100,000 in Losses Have Opportunity to Join Fox Factory Holding Corp. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $FOXF--FOXF Investors with $100,000 in Losses Have Opportunity to Join Fox Factory Holding Corp. Fraud Investigation with SBS Law.
JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $JNJ--JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law.
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $SNDX--SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
STT Investors with $100,000 in Losses Have Opportunity to Join State Street Corporation Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $STT--STT Investors with $100,000 in Losses Have Opportunity to Join State Street Corporation Fraud Investigation with SBS Law.
New Scientific Evidence Presented at ANESTHESIOLOGY 2026 Strengthens the Case for Senzime's TetraGraph and Quantitative Neuromuscular Monitoring
UPPSALA, SE AND SAN DIEGO, CA / ACCESS Newswire / October 17, 2026 / Senzime (STO:SEZI) (OTCQX:SNZZF) Senzime AB (publ), a global leader in precision-based patient monitoring solutions, today announced new scientific data presented at ANESTHESIOLOGY 2026, the annual meeting of the American Society of Anesthesiologists (ASA). The research highlights important clinical and economic aspects of quantitative neuromuscular monitoring, including the benefits of Senzime's proprietary TetraGraph technology...
JinkoSolar Unveils Tiger Neo 5.0 All-Black Residential Solar Module with 25.52% Efficiency
SHANGRAO, China, Oct. 17, 2026 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), today unveiled Tiger Neo 5.0, an all-black residential solar module built on its all-new TAC technology.
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programs Latest long-term and real-world data with SKYRIZI (risankizumab) and RINVOQ (upadacitinib) provide additional insight into clinical and endoscopic outcomes over approximately three years in moderately to severely active Crohn's disease and ulcerative colitis New data evaluating endoscopic remission with investigational dual-targeting therapy ABBV-466 in patients with moderate-to-severe Crohn's disease will also be presented NORTH CHICAGO, Ill., Oct. 17, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain...
Ballard Announces Q3 2026 Results Conference Call
VANCOUVER, BC, Oct. 16, 2026 /PRNewswire/ -- Ballard Power Systems (NASDAQ: BLDP) (TSX: BLDP) will hold a conference call on Monday November 16th, 2026 at 8:00 a.m. Pacific Time (10:00 a.m.
Navan Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Navan, Inc. - NAVN
NEW ORLEANS, Oct. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
NIP Group Inc. Announces Results of Extraordinary General Meeting
ABU DHABI, United Arab Emirates, Oct. 16, 2026 (GLOBE NEWSWIRE) -- NIP Group Inc. (“NIP Group” or the “Company”) (NASDAQ: NIPG), a leading digital entertainment company, today announced that the Company's extraordinary general meeting of shareholders (the “EGM”) was held in Hong Kong on October 16, 2026. During the EGM, the following proposed resolutions were duly passed: by a special resolution that, subject to the passing of Resolution 2, the Company's authorized share capital be increased FROM US$200,000 divided into 2,000,000,000 shares comprising (i) 1,756,459,263 Class A ordinary shares of a par value of US$0.0001 each (the “Class A Ordinary Shares”), (ii) 148,331,658 Class B1 ordinary shares of a par value of US$0.0001 each (the “Class B1 Ordinary Shares”) and (iii) 95,209,079 Class B2 ordinary shares of a par value of US$0.0001 each (the “Class B2 Ordinary Shares”), each of such class or classes (however designated) as the Company's board of directors may determine in accordance with the memorandum and articles of association of the Company then in effect TO US$1,000,000 divided into 10,000,000,000 shares comprising (i) 8,782,296,315 Class A Ordinary Shares, (ii) 741,658,290 Class B1 Ordinary Shares and (iii) 476,045,395 Class B2 Ordinary Shares, each of such class or classes (however designated) as the Company's board of directors may determine in accordance with the memorandum and articles of association of the Company then in effect, by the creation of (i) 7,025,837,052 Class A Ordinary Shares, (ii) 593,326,632 Class B1 Ordinary Shares, and (iii) 380,836,316 Class B2 Ordinary Shares...
Battery X Metals Highlights Participation at X Takeover 2026, an Electric Vehicle and Emerging Technology Event Held at Tesla's Gigafactory Texas, Providing Exposure to Industry Perspectives and Technology Developments
News Release Highlights: Battery X Metals attended X Takeover 2026, an independently organized electric vehicle and emerging technology community event held at Tesla's Gigafactory Texas in Austin, Texas. The event brought together enthusiasts, entrepreneurs, and industry participants for programming on electric mobility, energy, robotics, artificial intelligence and space technology, including presentations from notable automotive and technology industry figures...
Vanta Closes Second Tranche of Private Placement Financing and Welcomes Launch of First U.S.-Listed Peptide ETF, Highlighting Growing Recognition of Peptide Industry
VANCOUVER, BC / ACCESS Newswire / October 16, 2026 / Vanta Holdings Inc. (CSE:VNTA)(OTC:VNTXF)(FSE:7BC, WKN:A4205J) ("Vanta" or the "Company"), a consumer health sciences and longevity company focused on preventative wellness and healthspan extension, and parent of the Vanta premium longevity brand, announces that, further to its news releases dated May 29, 2026 , and August 21, 2026 , the Company has closed, effective October 15, 2026, the second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Private Placement"), through the issuance of 210,000 units of the Company (each, a "Unit") at a price of $1.00 per Unit, for aggregate gross proceeds of $210,000. Each Unit consists of one common share in the capital of the Company (each, a "Share") and one transferable common share purchase warrant (each, a "Warrant")...
Align Technology Wins Significant Patent Infringement Case Against Angelalign at Unified Patent Court
SAN JOSE, Calif. & TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (“Align”) (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign System of clear aligners, welcomes the decision of the Unified Patent Court (“UPC”) finding that aligner systems incorporating Angelalign's Torque Ridges feature infringe Align's European Patent EP 2 237 738 B1, which relates to Align's Power Ridge technology.In August 2025, Align initiated patent infring...
Silver Pony Announces Strategic Offering of Units for up to $1,000,000 Including Significant Investor Doug Casey
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2026) - Silver Pony Resources Corp. (CSE: PONY) (FSE: BJ40) (OTCID: PONIF) (formerly Carlyle Commodities Corp.) ("Silver Pony" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement (the "Offering") of up to 5,882,352 units (each, "Unit") at a price of $0.17 per Unit for aggregate gross proceeds of up to $1,000,000. Each Unit will consist of one common share of the Company (a "Share") and one transferable common share purchase warrant (a "Warrant")...
Blaize Holdings, Inc. Announces Distribution of Series B Preferred Stock to Holders of its Common Stock Intended to Facilitate a Reverse Stock Split, if Necessary
SAN JOSE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Blaize Holdings, Inc. (NASDAQ: BZAI, NASDAQ: BZAIW) (“Blaize,” the “Company,” “we,” “us,” and “our”), a leader in programmable, energy-efficient AI computing, announced today that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.0001 per share, for each outstanding share of Blaize common stock held of record on October 26, 2026. The outstanding shares of Series B Preferred Stock will vote together with the outstanding shares of the Company's common stock as a single class exclusively with respect to any proposal to adopt an amendment to the Company's certificate of incorporation to reclassify the outstanding shares of the Company's common stock into a smaller number of shares of such common stock at a ratio specified in or determined in accordance with the terms of any such amendment (a “Reverse Stock Split Proposal”), as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the foregoing matter (an “Adjournment Proposal”), and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law. Subject to certain limitations, each outstanding share of Series B Preferred Stock will have 1,000,000 votes per share (or 1,000 votes per one one-thousandth of a share of Series B Preferred Stock)...
GreenPower Announces Issuance of Series B Convertible Preferred Shares in Settlement of Convertible Debentures and Issuance of Shares for Accrued Interest and Dividends
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2026) - GreenPower Motor Company Inc. (NASDAQ: GP) ("GreenPower" or the "Company"), a leading manufacturer and distributor of all-electric, purpose-built, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, today announces that it has converted (the "Preferred Share Offering") the principal of convertible debentures (the "Debentures") in the aggregate amount of $1,999,750 owed to certain creditors into an aggregate of 2,105 series B convertible preferred shares (each, a "Series B Convertible Preferred Share"), with a stated value of USD $1,000 per share, for a purchase price of US$1,999,750 and a stated value of US$2,105,000. The Series B Convertible Preferred Shares have a dividend rate of 9% per annum and each Series B Convertible Preferred Share is eligible to be converted into common shares of the Company (each, a "Share") at 105% of the stated amount of the Series B Convertible Preferred Share and are convertible at US$1.975 per Share, subject to adjustment as provided for in the rights and restrictions of the Series B Convertible Preferred Shares...
Robbins LLP Urges Investors Who Lost Money Investing in Qfin Holdings, Inc. to Contact the Firm for Information About Their Rights Against QFIN
SAN DIEGO--(BUSINESS WIRE)---- $QFIN #QFIN--The complaint alleges that Qfin Holdings, Inc. misled investors regarding the impact of the new PRC regulatory guidance on its business prospects.
Trident Provides Updated Information Regarding Its Marketing Engagement with Freedom Financial Research, LLC
Vancouver, BC, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Trident Resources Corp. (TSXV: ROCK) (OTCQB: TRDTF) (Frankfurt: 6BP0) (“Trident” or the “Company”) announces that, further to its news release dated September 21, 2026 (the “Prior Release”), and at the request of the TSX Venture Exchange (the “TSXV”), it is providing updated and additional information regarding its engagement of Freedom Financial Research, LLC (“FFR”) to provide marketing and investor awareness services to the Company. This news release restates, in full, the disclosure regarding the FFR engagement contained in the Prior Release, as updated and supplemented below, and supersedes that disclosure...
Agereh Technologies Inc. Announces Private Placement Offering of $600,000
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2026) - Agereh Technologies Inc. (TSXV: AUTO) ("Agereh" or the "Company") is pleased to announce a private placement financing of up to 24,000,000 units of the Company ("Units") at a price of $0.025 per Unit for gross proceeds of up to $600,000 (the "Offering"). Each Unit under the Offering will consist of one (1) common share of the Company (each a "Share") and one (1) common share purchase warrant of the Company (each a "Warrant"), with each Warrant entitling the holder to purchase one (1) additional Share at a price of $0.05 per Share for a period of two (2) years from the date of issue...
Rubico Announces $8.5 Million Registered Direct Offering of Senior Convertible Notes and Warrants
ATHENS, Greece, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Rubico Inc. (Nasdaq: RUBI) (the "Company," "Rubico," “we” or “us”), a global provider of shipping transportation services specializing in the ownership of vessels, today announced it has entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor (the “Holder”) to issue senior convertible notes (the “Notes”) in the aggregate principal amount of $9,444,444, bearing an original issue discount of 10% and warrants (the “Warrants”) to purchase common shares with an aggregate initial cash exercise price of $9,444,444. The Company expects to issue such Notes and Warrants on or about October 19, 2026 (the “First Tranche Closing”), subject to the satisfaction of customary closing conditions. The Company will receive gross proceeds of $8,500,000 at the First Tranche Closing...
XCF Global CEO Updates Shareholders Following Recent Market Volatility
HOUSTON, TX / ACCESS Newswire / October 16, 2026 / XCF Global, Inc. (NASDAQ:SAFX) today shared the following update with shareholders: "We understand that the recent volatility and decline in our share price have been concerning and frustrating for our shareholders, and we take those concerns seriously. We value the confidence our shareholders have placed in XCF and believe it is important to communicate openly about the progress we are making and the priorities that continue to guide us...
VCI Global Advances AI Infrastructure and Token Services Strategy; Strengthens Balance Sheet in 1H2026
Total Equity Increases 19.2% to US$114.70 Million as Company Prioritizes Expansion Across GPU Computing and AI Model Service Total Equity Increases 19.2% to US$114.70 Million as Company Prioritizes Expansion Across GPU Computing and AI Model Service
LQR House Inc. Announces CEO Transition
Sean Dollinger Steps Down as Chief Executive Officer Leo Chen Named CEO MIAMI BEACH, FL / ACCESS Newswire / October 16, 2026 / LQR House Inc. (the "Company", "LQR House" or "LQR") (NASDAQ:YHC) today announced that Sean Dollinger has stepped down as Chief Executive Officer, effective October 16, 2026. Leo Chen will become Chief Executive Officer, effective immediately...
Phaos Technology Holdings (Cayman) Limited Announces Filing of Annual Report on Form 20-F for Fiscal Year 2026
SINGAPORE, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Phaos Technology Holdings (Cayman) Limited (NYSE American: POAS) (“Phaos” or “the Company”), an advanced microscopy technology company headquartered in Singapore, announced that it filed its annual report on Form 20-F (the “Annual Report”) for the fiscal year ended April 30, 2026 with the U.S. Securities and Exchange Commission (the “SEC”) on August 31, 2026...
Five Star Bancorp Declares Third Quarter Cash Dividend
RANCHO CORDOVA, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Five Star Bancorp (Nasdaq: FSBC) (“Five Star” or the “Company”), a holding company that operates through its wholly owned banking subsidiary, Five Star Bank (the "Bank"), announced today the declaration of a cash dividend of $0.25 per share on the Company's voting common stock. The dividend is expected to be paid on November 9, 2026, to shareholders of record as of November 2, 2026...
MongoDB Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of MongoDB, Inc. - MDB
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into MongoDB, Inc. (NasdaqGM: MDB). According to a securities class action complaint filed against the Company, in the first quarter of fiscal year 2024, in an effort to sustain MongoDB's rapid growth, the Company implemented a new go-to-market strategy that eliminated sales incentives for...
KBRA Assigns Preliminary Ratings to Angel Oak Mortgage Trust 2026-6 (AOMT 2026-6)
NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns preliminary ratings to ten classes of mortgage-backed certificates from Angel Oak Mortgage Trust 2026-6 (AOMT 2026-6), a $250.6 million non-prime RMBS transaction. The underlying collateral, comprised of 381 residential mortgages, and includes a meaningful concentration of collateral that KBRA considers to be “non-prime.” All the loans are either classified as non-qualified mortgages (62.8%) or exempt (37.2%) from the Ability-to-Repay/Qualified Mortgage r...
Alignment Healthcare Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alignment Healthcare, Inc. - ALHC
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Alignment Healthcare, Inc. (“Alignment” or the “Company”) (NasdaqGS: ALHC). On July 8, 2026, reports emerged that a former Alignment executive had filed a whistleblower lawsuit alleging that the Company deliberately misclassified $8 million to $10 million in routine operating expens...
Copper Lake Announces Closing of Second and Final Tranche of Previously Announced Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - October 16, 2026) - Copper Lake Resources Ltd. (TSXV: CPL) (FSE: W0I0) ("Copper Lake" or the "Company") announces that it has closed the second and final tranche (the "Final Tranche") of its non-brokered private placement (the "Offering") previously announced on September 3, 2026 (the "Private Placement")...
Canamera Announces Closing of Rights Offering
Edmonton, Alberta--(Newsfile Corp. - October 16, 2026) - Canamera Energy Metals Corp. (CSE: EMET) (OTCQB: EMETF) (FSE: 4LF0) ("Canamera" or the "Company") is pleased to announce that it has closed (the "Closing") its previously announced rights offering (the "Rights Offering") to eligible holders (the "Shareholders") of its common shares (each, a "Common Share"). At Closing, the Company had 153,099,226 Common Shares issued and outstanding, including 76,524,613 Common Shares issued pursuant to the Rights Offering at a price of $0.01 per Common Share for aggregate gross proceeds of $765,246.13...
Terra Clean Energy to Present at the Centurion One Capital 4th Annual Bahamas Summit
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2026) - Terra Clean Energy Corp. ("Terra Clean Energy" or the "Company") (CSE: TCEC) (OTCQB: TCEFF) (FSE: C9O0) is is pleased to announce it will be presenting at the Centurion One Capital 4th Annual Bahamas Summit, a two-day invitation-only event taking place at the exclusive Rosewood Baha Mar Hotel from Monday, October 19th to Wednesday, October 21st, 2026, in Nassau, Bahamas. Greg Cameron, President and CEO of the Company is scheduled to present during the two-day event...
San Lorenzo Announces Upsize of Private Placement to Up to $80 Million
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Oct. 16, 2026 (GLOBE NEWSWIRE) -- San Lorenzo Gold Corp. ("San Lorenzo" or the "Company") (TSXV: SLG; OTC: SNLGF) is pleased to announce that the Company has increased the size of its previously announced best-efforts private placement from up to 7,547,200 to up to 15,094,400 common shares of the Company (the "Offered Shares") at a price of $5.30 per Offered Share (the "Issue Price") for aggregate gross proceeds of up to $80,000,320 (the "Offering"). The Offering is led by SCP Resource Finance LP and National Bank Financial Inc. as lead agents (the "Lead Agents"), on behalf of a syndicate of agents (together with the Lead Agents, the "Agents")...
UL Solutions Warns of GFCI and Duplex Wall Outlets Modified by Third Parties to Include Built-in Cameras
NORTHBROOK, Ill.--(BUSINESS WIRE)--UL Solutions (NYSE: ULS), a global leader in applied safety science, issued a public notice regarding ground fault circuit interrupter (GFCI) and duplex wall outlets that were UL Certified by the original manufacturer and bear the UL Mark, but were subsequently modified by third parties to include hidden cameras in the construction. The GFCI and duplex wall outlets employing cameras have not been evaluated by UL Solutions and are not authorized to bear the UL...
Initial Closing of US$3.4 Million Private Placement
ACCESS Newswire / October 16, 2026 / Gabriel Resources Ltd. (TSXV:GBU) ("Gabriel" or the "Company") announces an initial closing (the "Initial Closing") of its previously announced non-brokered private placement of up to 58,471,757 units (each, a "Unit") at C$0.0825 per Unit (the "Subscription Price"), for aggregate subscriptions of up to US$3.4 million (approximately C$4.82 million) (the "Offering")...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan...
EQB Inc. Appoints Vivian Abdelmessih to the Board of Directors
Kishore Kapoor, current EQB Board member and Chair of the Risk & Capital Committee, to step down effective January 1, 2027 TORONTO, Oct. 16, 2026 /PRNewswire/ -- The Board of Directors of EQB Inc. and Equitable Bank (collectively "EQB") today announced that it will appoint Vivian Abdelmessih to the Board of Directors and Chair of the Board's Risk & Capital Committee. Ms. Abdelmessih is a seasoned risk management and financial services executive with extensive experience in enterprise risk management, capital oversight, regulatory compliance and corporate governance...
NiobiumX Mining Inc. Announces Retraction of Recent Marketing Materials
TORONTO, ON / ACCESS Newswire / October 16, 2026 / NiobiumX Mining Inc. (CSE:NIOX)(OTCQB:NIOXF)(FSE:O7D0) ("NiobiumX" or the "Company") announces that, at the request of the Canadian Securities Exchange (the "CSE"), it has retracted two paid promotional articles prepared and disseminated on the Company's behalf by Altura Media Co. Inc. ("Altura"): (i) "The Defense Market is Wall Street's Best Kept Secret", published on www.wallsttrends.com and associated landing pages ("Article 1"); and (ii) "Niobium: Ohne diesen Rohstoff funktioniert keine moderne Verteidigungstechnologie" ("Article 2" and, together with Article 1, the "Promotional Materials"). The Promotional Materials contained several instances of unbalanced disclosure, including speculative statements respecting a "valuation gap" and a potential "revaluation" of the Company, and did not comply with National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101"), including the requirement for review and sign-off on the disclosure by a qualified person...
Avicanna Transitions US Listing to OTCQB
TORONTO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQB: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products announces that in the US, the Company will transition to OTCQB effective October 16, 2026...
XCF Global Completes Business Combination with Southern Energy Renewables and DevvStream, Creating Vertically Integrated Alternative Energy Platform
The combination brings together both today-and future technology alternative fuel production capability, biomass-to-fuels development and environmental-asset monetization to support domestic energy security, reduced carbon emissions and alternative uses for agricultural waste products. With the closing of the business combination, XCF is updating its 2027 financial outlook to reflect gross product sales of $650 to 700 million, net revenue of $120- 130 million and EBITDA of $70-75 million.1 XCF believes that the combination will create meaningful shareholder value resulting from combined target 2030 annual gross product sales of more than $1.4 billion, net revenue of more than $400 million and EBITDA of more than $300m...
Granting of Incentive Stock Options
VANCOUVER, British Columbia, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) announces that pursuant to the Company's stock option plan, 5,162,338 incentive stock options exercisable at $0.225 per share for a period of five years have been granted to directors, officers, employees and consultants of the Company...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 15, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 111,615 shares of Iovance's common stock to twenty-one new, non-executive employees...
Navigator Gas Announces Shareholder Meeting to Approve Change of Domicile to England and Wales
LONDON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Navigator Holdings Ltd. (described herein as “Navigator Gas” or the “Company”) (NYSE: NVGS) announced today that, on October 8, 2026, it entered into an Agreement and Plan of Merger (the “Merger Agreement”) with its wholly owned English subsidiary, Navigator Gas plc (the “New Parent”), and Navigator Gas Merger Co Inc., a wholly owned subsidiary of the New Parent (the “Merger Sub”)...
Archimedes Tech SPAC Partners II Co. Announces Shareholder Approval of Proposed Business Combination with Forge Nano, Inc.
CLAYMONT, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Archimedes Tech SPAC Partners II Co. (Nasdaq: ATII) (“Archimedes II” or “ATII”), a publicly traded special purpose acquisition company, today announced that at the Extraordinary General Meeting (the “Meeting”) held today, October 16, 2026, ATII's shareholders voted to approve the previously announced business combination (the “Business Combination”) between ATII and Forge Nano, Inc. (“Forge Nano”), as well as all other proposals related to the Business Combination considered and voted upon at the Meeting...
Kane Biotech Announces $250,000 Insider Loan
Unsecured, non-interest-bearing loan provides additional working capital support Unsecured, non-interest-bearing loan provides additional working capital support
LGI Homes Announces the Opening of New Community in Weatherford, Texas
LGI Homes announces the opening of Chisolm Park, located in Weatherford, Texas. This new community offers an impressive lineup of single-family homes.
TC Energy to host third quarter 2026 conference call on Nov. 5
CALGARY, Alberta, Oct. 16, 2026 (GLOBE NEWSWIRE) -- TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) will hold a teleconference and webcast on Thursday, Nov. 5, 2026, to discuss its third quarter financial results. The event will also include an update to the Company's financial outlook along with other developments...